DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
IBERDOMIDE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Sarcoidosis; Smoldering Multiple Myeloma; Multiple Myeloma
Unknown
IBERDOMIDE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
79L3645KFI
Molecule Type:
Small molecule
Molecular Formula:
C25H28ClN3O5
Molecular Weight:
485.97
AlogP:
1.86
PSA:
88.18
HBD:
1.0
HBA:
#RotB:
6.0
Source:
ALVESPIMYCIN
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Heat shock protein HSP90 inhibitor
ALVESPIMYCIN
×
Maximum Phase:
2
First Approval:
None
UNII:
001L2FE0M3
Molecule Type:
Small molecule
Molecular Formula:
C32H48N4O8
Molecular Weight:
616.76
AlogP:
1.91
PSA:
169.52
HBD:
4.0
HBA:
#RotB:
7.0
Source:
FLUBROBENGUANE F18
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
FLUBROBENGUANE F18
×
Maximum Phase:
2
First Approval:
None
UNII:
8LF7W971UM
Molecule Type:
Small molecule
Molecular Formula:
C11H15BrFN3O
Molecular Weight:
303.17
AlogP:
2.17
PSA:
71.13
HBD:
3.0
HBA:
#RotB:
6.0
Source:
ELVUCITABINE
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis B, Chronic; HIV Infections
DNA polymerase/reverse transcriptase inhibitor
ELVUCITABINE
×
Maximum Phase:
2
First Approval:
None
UNII:
M09BUF90C0
Molecule Type:
Small molecule
Molecular Formula:
C9H10FN3O3
Molecular Weight:
227.19
AlogP:
-0.59
PSA:
90.37
HBD:
2.0
HBA:
#RotB:
2.0
Source:
QLT0074
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
QLT0074
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UR-63325
2
Small molecule
Investigational
Unknown
Unknown
Rhinitis, Allergic, Seasonal
Histamine H4 receptor antagonist
UR-63325
×
Maximum Phase:
2
First Approval:
None
UNII:
B61N8R7TDH
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GC-4711
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms
Unknown
GC-4711
×
Maximum Phase:
2
First Approval:
None
UNII:
FW5T90VM32
Molecule Type:
Small molecule
Molecular Formula:
C27H45MnN5O4
Molecular Weight:
558.63
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
PCS-499
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Renal Insufficiency, Chronic; Necrobiosis Lipoidica
Unknown
PCS-499
×
Maximum Phase:
2
First Approval:
None
UNII:
FLV771E8ZV
Molecule Type:
Small molecule
Molecular Formula:
C13H20N4O3
Molecular Weight:
285.36
AlogP:
-0.02
PSA:
82.05
HBD:
1.0
HBA:
#RotB:
5.0
Source:
HEMOGLOBIN GLUTAMER
2
Small molecule
Investigational
Unknown
Unknown
Coronary Disease; Peripheral Vascular Diseases
Unknown
HEMOGLOBIN GLUTAMER
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RUTIN
2
Small molecule
Investigational
Unknown
Unknown
Cardiovascular Diseases; Prostatic Neoplasms, Castration-Resistant
Unknown
RUTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
5G06TVY3R7
Molecule Type:
Small molecule
Molecular Formula:
C27H30O16
Molecular Weight:
610.52
AlogP:
-1.69
PSA:
269.43
HBD:
10.0
HBA:
#RotB:
6.0
Source:
AFEGOSTAT TARTRATE
2
Small molecule
Investigational
Unknown
Unknown
Gaucher Disease
Beta-glucocerebrosidase stabiliser
AFEGOSTAT TARTRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
285ZJJ9773
Molecule Type:
Small molecule
Molecular Formula:
C10H19NO9
Molecular Weight:
297.26
AlogP:
-2.08
PSA:
72.72
HBD:
4.0
HBA:
#RotB:
1.0
Source:
PRATOSARTAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Solute carrier family 22 member 12 inhibitor
PRATOSARTAN
×
Maximum Phase:
2
First Approval:
None
UNII:
66VLQ6E6DL
Molecule Type:
Small molecule
Molecular Formula:
C25H26N6O
Molecular Weight:
426.52
AlogP:
4.64
PSA:
89.35
HBD:
1.0
HBA:
#RotB:
6.0
Source:
A-002
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
A-002
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
P
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
P
×
Maximum Phase:
2
First Approval:
None
UNII:
N939YFB9KP
Molecule Type:
Small molecule
Molecular Formula:
C13H20N4O3
Molecular Weight:
280.33
AlogP:
-0.02
PSA:
82.05
HBD:
1.0
HBA:
#RotB:
5.0
Source:
RADIPRODIL
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia; Spasms, Infantile
Glutamate NMDA receptor; GRIN1/GRIN2B antagonist
RADIPRODIL
×
Maximum Phase:
2
First Approval:
None
UNII:
5XGC17ZKUF
Molecule Type:
Small molecule
Molecular Formula:
C21H20FN3O4
Molecular Weight:
397.41
AlogP:
2.68
PSA:
95.41
HBD:
2.0
HBA:
#RotB:
3.0
Source:
CR 1447
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Androgen Receptor agonist
CR 1447
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BTRX-335140
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major
Kappa opioid receptor antagonist
BTRX-335140
×
Maximum Phase:
2
First Approval:
None
UNII:
XK5ILZ28KI
Molecule Type:
Small molecule
Molecular Formula:
C25H32FN5O2
Molecular Weight:
453.56
AlogP:
4.34
PSA:
76.31
HBD:
1.0
HBA:
#RotB:
5.0
Source:
TARAFENACIN
2
Small molecule
Investigational
Unknown
Unknown
Urinary Bladder, Overactive
Muscarinic acetylcholine receptor M3 antagonist
TARAFENACIN
×
Maximum Phase:
2
First Approval:
None
UNII:
LDV98UN52Y
Molecule Type:
Small molecule
Molecular Formula:
C21H20F4N2O2
Molecular Weight:
408.39
AlogP:
4.48
PSA:
32.78
HBD:
0.0
HBA:
#RotB:
4.0
Source:
DIMETHYLAMINOETHANOL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DIMETHYLAMINOETHANOL
×
Maximum Phase:
2
First Approval:
None
UNII:
2N6K9DRA24
Molecule Type:
Small molecule
Molecular Formula:
C4H11NO
Molecular Weight:
89.14
AlogP:
-0.46
PSA:
23.47
HBD:
1.0
HBA:
#RotB:
2.0
Source:
KOS-1584
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Tubulin stabiliser
KOS-1584
×
Maximum Phase:
2
First Approval:
None
UNII:
82481G197K
Molecule Type:
Small molecule
Molecular Formula:
C27H39NO5S
Molecular Weight:
489.68
AlogP:
5.04
PSA:
96.72
HBD:
2.0
HBA:
#RotB:
2.0
Source:
L-SULFORAPHANE
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Unknown
L-SULFORAPHANE
×
Maximum Phase:
2
First Approval:
None
UNII:
7J94TPZ10L
Molecule Type:
Small molecule
Molecular Formula:
C6H11NOS2
Molecular Weight:
177.29
AlogP:
1.25
PSA:
29.43
HBD:
0.0
HBA:
#RotB:
5.0
Source:
APRICOXIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms
Cyclooxygenase-2 inhibitor
APRICOXIB
×
Maximum Phase:
2
First Approval:
None
UNII:
5X5HB3VZ3Z
Molecule Type:
Small molecule
Molecular Formula:
C19H20N2O3S
Molecular Weight:
356.45
AlogP:
3.5
PSA:
74.32
HBD:
1.0
HBA:
#RotB:
5.0
Source:
BLARCAMESINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BLARCAMESINE
×
Maximum Phase:
2
First Approval:
None
UNII:
9T210MMZ3F
Molecule Type:
Small molecule
Molecular Formula:
C19H23NO
Molecular Weight:
281.4
AlogP:
3.53
PSA:
12.47
HBD:
0.0
HBA:
#RotB:
4.0
Source:
ALVELESTAT
2
Small molecule
Investigational
Unknown
Unknown
Hematologic Neoplasms; Severe Acute Respiratory Syndrome; Bronchiectasis; Cystic Fibrosis; Pulmonary Disease, Chronic Obstructive
Unknown
ALVELESTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
6Y5629322X
Molecule Type:
Small molecule
Molecular Formula:
C25H22F3N5O4S
Molecular Weight:
545.54
AlogP:
3.29
PSA:
115.95
HBD:
1.0
HBA:
#RotB:
6.0
Source:
CP-724714
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasm Metastasis
Receptor protein-tyrosine kinase erbB-2 inhibitor
CP-724714
×
Maximum Phase:
2
First Approval:
None
UNII:
I05QZ0S4V3
Molecule Type:
Small molecule
Molecular Formula:
C27H27N5O3
Molecular Weight:
469.55
AlogP:
4.95
PSA:
98.26
HBD:
2.0
HBA:
#RotB:
9.0
Source:
ORNITHINE PHENYLACETATE
2
Small molecule
Investigational
Unknown
Unknown
Liver Cirrhosis; Liver Failure, Acute
Unknown
ORNITHINE PHENYLACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
9D6YZ105SN
Molecule Type:
Small molecule
Molecular Formula:
C13H20N2O4
Molecular Weight:
268.31
AlogP:
-0.86
PSA:
89.34
HBD:
3.0
HBA:
#RotB:
4.0
Source:
ERTEBEREL
2
Small molecule
Investigational
Unknown
Unknown
Prostatic Hyperplasia; Schizophrenia
Estrogen receptor beta agonist
ERTEBEREL
×
Maximum Phase:
2
First Approval:
None
UNII:
2ZUL6758TZ
Molecule Type:
Small molecule
Molecular Formula:
C18H18O3
Molecular Weight:
282.34
AlogP:
4.12
PSA:
49.69
HBD:
2.0
HBA:
#RotB:
1.0
Source:
BCX-1777
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BCX-1777
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FENEBRUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Urticaria; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive
Tyrosine-protein kinase BTK inhibitor
FENEBRUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
E9L2885WUL
Molecule Type:
Small molecule
Molecular Formula:
C37H44N8O4
Molecular Weight:
664.81
AlogP:
3.57
PSA:
120.99
HBD:
2.0
HBA:
#RotB:
7.0
Source:
EVT-101
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder
Glutamate NMDA receptor; GRIN1/GRIN2B antagonist
EVT-101
×
Maximum Phase:
2
First Approval:
None
UNII:
B55T45AA8F
Molecule Type:
Small molecule
Molecular Formula:
C16H15Cl2F3N4
Molecular Weight:
391.22
AlogP:
3.77
PSA:
43.6
HBD:
0.0
HBA:
#RotB:
4.0
Source:
OLMUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
OLMUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
CHL9B67L95
Molecule Type:
Small molecule
Molecular Formula:
C26H26N6O2S
Molecular Weight:
486.6
AlogP:
5.1
PSA:
82.62
HBD:
2.0
HBA:
#RotB:
7.0
Source:
VALEMETOSTAT TOSYLATE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia-Lymphoma, Adult T-Cell; Lymphoma
Unknown
VALEMETOSTAT TOSYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
6N79I7X5II
Molecule Type:
Small molecule
Molecular Formula:
C33H42ClN3O7S
Molecular Weight:
660.23
AlogP:
4.49
PSA:
83.66
HBD:
2.0
HBA:
#RotB:
5.0
Source:
RIVIPANSEL SODIUM
2
Small molecule
Investigational
Unknown
Unknown
Anemia, Sickle Cell
Unknown
RIVIPANSEL SODIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
11AEN6VWDN
Molecule Type:
Small molecule
Molecular Formula:
C58H70N6Na4O31S3
Molecular Weight:
1535.37
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
SAR-125844
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Hepatocyte growth factor receptor inhibitor
SAR-125844
×
Maximum Phase:
2
First Approval:
None
UNII:
XH93U6NIJE
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FARAMPATOR
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Depressive Disorder, Major; Schizophrenia
Glutamate receptor ionotropic AMPA positive allosteric modulator
FARAMPATOR
×
Maximum Phase:
2
First Approval:
None
UNII:
7X6P5N8K2L
Molecule Type:
Small molecule
Molecular Formula:
C12H13N3O2
Molecular Weight:
231.25
AlogP:
1.85
PSA:
59.23
HBD:
0.0
HBA:
#RotB:
1.0
Source:
1
2
…
116
117
118
119
120
121
122
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA